PPP1R3A Variant Lowers Muscle Glycogen
Author Information
Author(s): David B. Savage, Lanmin Zhai, Balasubramanian Ravikumar, Cheol Soo Choi, Johanna E. Snaar, Amanda C. McGuire, Sung-Eun Wou, Gemma Medina-Gomez, Sheene Kim, Cheryl Bock, Dyann M. Segvich, Antonio Vidal-Puig, Nick J. Wareham, Gerald I. Shulman, Fredrik Karpe, Roy Taylor, Bartholomew A. Pederson, Peter J. Roach, Stephen O'Rahilly, Anna A. DePaoli-Roach
Primary Institution: University of Cambridge
Hypothesis
What are the molecular and physiological consequences of the PPP1R3A genetic variant on glycogen synthesis?
Conclusion
The PPP1R3A C1984ΔAG mutation impairs glycogen synthesis and decreases glycogen levels in human skeletal muscle.
Supporting Evidence
- The PPP1R3A FS mutation was found in 1.46% of a UK white population.
- Carriers of the mutation had 65% lower muscle glycogen levels compared to non-carriers.
- Mice with the equivalent mutation also showed a 40% reduction in muscle glycogen content.
- The mutation affects the binding of RGL to glycogen and glycogen synthase, leading to decreased glycogen synthesis.
- Despite lower glycogen levels, blood glucose and insulin levels remained normal in human carriers.
Takeaway
A common genetic change can make it harder for muscles to store energy, which might be important for understanding diabetes.
Methodology
The study involved genotyping participants and using in vivo 13C magnetic resonance spectroscopy to measure muscle glycogen levels.
Limitations
The study primarily focused on a specific population, which may limit the generalizability of the findings.
Participant Demographics
Participants were healthy adults aged 30 to 50 from the UK, primarily of white ethnicity.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website